Windtree Therapeutics, Inc. (WINT)
| Market Cap | 84.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.49M |
| Shares Out | 16.58M |
| EPS (ttm) | -2.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $4.96 |
| Previous Close | $5.03 |
| Change ($) | -0.08 |
| Change (%) | -1.49% |
| Day's Open | 5.69 |
| Day's Range | 4.91 - 5.69 |
| Day's Volume | 170,164 |
| 52-Week Range | 4.80 - 10.06 |
News
Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 16, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions f...
WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and me...
Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher on Wednesday. The company announced the initial European trial sites activated for its AEROSURF Bridging study and a collabor...
About WINT
Windtree Therapeutics, a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infant... [Read more...]
| Industry Biotechnology | IPO Date Aug 8, 1995 |
| CEO Craig E. Fraser | Employees 31 |
| Stock Exchange NASDAQ | Ticker Symbol WINT |
Financial Performance
In 2019, WINT's revenue was $198,000, a decrease of -88.93% compared to the previous year's $1.79 million. Losses were -$27.48 million, 33.8% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for WINT stock is "Strong Buy" and the 12-month stock price forecast is 12.13.